ReviewActa pharmacologica Sinica2026
Adenosine receptor signaling in vascular diseases: from molecular mechanisms to targeted therapeutics.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular diseases include disorders affecting arteries, veins, and capillaries, and remain the main cause of morbidity and mortality worldwide. The search for new therapeutic targets has led to the discovery of adenosine receptors as key regulators of the pathogenesis of several vascular conditions, including hypertension, atherosclerosis, abdominal aortic aneurysm, cerebral ischemia, and pathological angiogenesis. This review summarises the context-dependent functions of adenosine receptors in these diseases, with particular emphasis on mechanisms associated with endothelial-mesenchymal transition, vascular inflammation, and metabolic reprogramming. The therapeutic relevance of individual adenosine receptor subtypes is also discussed, including current preclinical evidence regarding receptor agonists and antagonists, as well as the potential value of combination-based approaches. Finally, current challenges and future research directions are considered, particularly the development of tissue-specific therapeutic strategies and the application of emerging technologies to improve the clinical translation of mechanistic findings.
Indexed as
Identifiers
42350779What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.